<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">423</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2020-15-2-108-112</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESOLUTION</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>РЕЗОЛЮЦИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Expert Council resolution on the specifics of multiple myeloma therapy during COVID-19 pandemic</article-title><trans-title-group xml:lang="ru"><trans-title>Резолюция Совета экспертов по особенностям терапии множественной миеломы в условиях пандемии COVID-19</trans-title></trans-title-group></title-group><pub-date date-type="pub" iso-8601-date="2020-07-16" publication-format="electronic"><day>16</day><month>07</month><year>2020</year></pub-date><volume>15</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>108</fpage><lpage>112</lpage><history><date date-type="received" iso-8601-date="2020-07-15"><day>15</day><month>07</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-07-15"><day>15</day><month>07</month><year>2020</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/423">https://oncohematology.abvpress.ru/ongm/article/view/423</self-uri><abstract xml:lang="en"><p>.</p></abstract><trans-abstract xml:lang="ru"><p>22 мая 2020 г. в дистанционном режиме состоялся Совет экспертов по проблемам терапии множественной миеломы в условиях пандемии COVID-19, проведенный в целях изменений и адаптации текущих подходов лечения в сложившейся эпидемиологической обстановке. В совещании приняли участие ведущие специалисты федеральных и региональных центров гематологии.</p></trans-abstract><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Kamkin E.G., Kostenko N.A., Karakulina E.V. et al. Prevention, diagnosis and treatment of new coronovirus infection (COVID-19). Temporary guidelines. Moscow: Ministry of Health of the Russian Federation, 2020. Version 6. 164 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Камкин Е.Г., Костенко Н.А., Каракулина Е.В. и др. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. М.: Министерство Здравоохранения Российской Федерации, 2020. Версия 6. 164 с.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Statistics on the incidence of new coronovirus infection in Russia, 2020. Available at: https://стопкоронавирус.рф (access date 05.22.2020) (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Статистика по заболеваемости новой коронавирусной инфекцией в России, 2020. Доступно по: https://стопкоронавирус.рф (дата обращения 22.05.2020).</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Liang W., Guan W., Chen R. et al. Cancer Patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335–7. DOI: 10.1016/S1470-2045(20)30096-6.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Dai M., Liu D., Miao Liu M. et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020. DOI: 10.1158/2159-8290.CD-20-0422.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>COVID-19 Registry for Hematological Malignancy Data Summaries. ASH RC Data Hub, 2020. Available at: https://www.ashresearchcollaborative.org/s/covid-19registry-data-summaries.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Blimark C., Holmberg E., Mellqvist U.H. et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015;100(1):107–13. DOI: 10.3324/haematol.2014.107714.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Heider U., Rademacher J., Kaiser M. et al. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma Leuk 2010;10(2):134–7. DOI: 10.3816/CLML.2010.n.019.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ying L., YinHui T., Yunliang Z., Sun H. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget 2017;8(28):46593–600. DOI: 10.18632/oncotarget.16235.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Nahi H., Chrobok M., Gran C. et al. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PLoS One 2019;14(2):e0211927. DOI: 10.1371/journal.pone.0211927.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Terpos E., Ntanasis-Stathopoulos I., Elalamy I. et al. Hematological findings and complications of COVID-19. Am J Hematol 2020. DOI: 10.1002/ajh.25829.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>COVID-19: Collaboration and Resilience Are Paying Off (March 26, 2020 UPDATE). International Myeloma Foundation (IMF), 2020. Available at: https://www.myeloma.org/drdurie-blog/covid-19-collaboration-resilience-arepaying-march-26-2020-update (access date 22.05.2020).</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>ESMO management and treatment adapted recommendations in the COVID-19 era: multiple myeloma. European Society for Medical Oncology (ESMO), 2020. Available at: https://www.esmo.org/guidelines/cancer-patient-managementduring-the-covid-19-pandemic/haematological-malignancies-multiplemyeloma-in-the-covid-19-era (access date 22.05.2020).</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>International Myeloma Society Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. International Myeloma Society (IMS), 2020. Available at: https://cms.cws.net/content/beta.myelomasociety.org/files/IMS%20recommendations%20for%20Physicians%20Final.pdf (access date 22.05.2020).</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>COVID-19 and Multiple Myeloma: Frequently Asked Questions. American Society of Hematology (ASH), 2020. Available at: https://www.hematology.org/covid-19/covid-19-and-multiple-myeloma (access date 22.05.2020).</mixed-citation></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases: monograph. Eds: I.V. Poddubnaya, V.G. Savchenko. Moscow: Russian Professional Society of Oncohematologists, 2018. 356 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний: монография. Под ред.: И.В. Поддубной, В.Г. Савченко. М.: Российское профессиональное общество онкогематологов, 2018. 356 с.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><mixed-citation>Avet-Loiseau H., Bahlis N.J., Chng W.J. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood 2017;130(24):2610–8. DOI: 10.1182/blood-2017-06-791228.</mixed-citation></ref></ref-list></back></article>
